Receptorial radiotherapy with 177Lu DOTATATE in somatostatine receptors positive tumours, a phase II study.

Trial Profile

Receptorial radiotherapy with 177Lu DOTATATE in somatostatine receptors positive tumours, a phase II study.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 09 Mar 2012

At a glance

  • Drugs Octreotate-Lu-177-DOTA-Tyr-3 (Primary)
  • Indications Adenocarcinoma; Tumours
  • Focus Therapeutic Use
  • Acronyms IRST 100.06
  • Most Recent Events

    • 09 Mar 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top